On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback